BioAge Labs, Inc.

BioAge Labs, Inc. is a clinical-stage biopharmaceutical company dedicated to extending healthy human lifespan by developing therapeutic product candidates that target the molecular causes of aging. Headquartered in Richmond, CA, the company focuses on addressing metabolic diseases through its innovative research and development efforts.

The company's pipeline includes BGE-102, an orally available, brain-penetrant small-molecule NLRP3 inhibitor currently being developed for cardiovascular risk and retinal diseases, including diabetic macular edema. BioAge is also actively developing long-acting injectable and oral small molecule APJ agonists for obesity, leveraging a human-first discovery platform that analyzes proprietary multi-omics data to identify novel targets and mechanisms of aging and disease.

In recent news, BioAge Labs reported positive Phase 1 data for BGE-102 in April 2026, demonstrating significant reductions in hsCRP, and announced an upsized $115.0 million public offering in January 2026. The company is led by Co-Founder and CEO Kristen Fortney, who was appointed in April 2015. BioAge Labs has also engaged in strategic collaborations, including a partnership with Novartis to identify drug targets related to aging and exercise biology, and previously with Eli Lilly for its azelaprag program. The company reported Q1 2026 financial results in May 2026, indicating a cash runway extending through 2029.